Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Keros Therapeutics (KROS) and the $19 Target: A Look at the Implied +70% Upside

Keros Therapeutics (KROS) and the $19 Target: A Look at the Implied +70% Upside

Key Takeaways

  • The central price target of $19 is the arithmetic mean of five current, attributable analyst price targets, not a single firm's forecast.
  • Shares of Keros Therapeutics, Inc. (KROS) were trading around $11 in mid-November 2026, meaning the target implies a roughly 70% move.
  • The five reviewed targets range from $16 to $23, while broader aggregator coverage extends the high end to roughly $25, reflecting a wide spread of opinion.
  • Supporting factors include a late-stage, Takeda-partnered lead asset (elritercept), a recently funded balance sheet, and milestone revenue that beat expectations.
  • Key risks are a pipeline-centric valuation with no approved products, repeated target cuts through 2026, and a stock still trading near its 52-week low.
  • For more detail on this ticker, explore Major News, Today's Price Move, Forecast, and Earnings pages.
  • Investors can also explore Trending AI Robots to monitor changing market conditions across thousands of tickers.

Analyst Price Targets and Consensus View

The $19 central target is a calculated average rather than a published consensus. Five recent, individually attributed targets were reviewed: Wedbush at $16 (Hold), Wells Fargo at $18 (Overweight), BofA at $18 (Neutral, raised from $17 in November 2026), H.C. Wainwright at $20 (Buy), and Leerink Partners at $23 (Outperform). The mean of those five figures is $19.00, with a range of $16 to $23. Separate aggregator datasets include additional coverage and show a high near $25 and averages between roughly $18.80 and $20.30. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The spread is meaningful. Cautious, Hold-rated analysts such as Wedbush anchor the low end at $16, while buy-rated firms justify targets above $20 on the value of the pipeline relative to a market capitalization near $200 million. The pattern through 2026 has been predominantly downward revision—Leerink cut from $30 to $23 and Wells Fargo from $20 to $18—so the targets themselves reflect reduced, not heightened, expectations.

Current Market Position and Path Toward the Target

Keros Therapeutics (KROS) traded near $11 in mid-November 2026, not far above a 52-week low of roughly $9.10 and well below its 52-week high around $22.55. Reaching $19 from about $11 requires an advance of roughly 70%, a very large move for any stock over a typical research horizon.

The path depends almost entirely on clinical execution. Keros has no approved products and generates revenue chiefly from collaboration and milestone payments, including a Takeda partnership on its lead asset, elritercept (KER-050), which is in late-stage development for myelodysplastic syndromes (MDS) and myelofibrosis. The company is also shifting focus to its wholly owned asset rinvatercept (KER-065), now in a Phase 2 study for Duchenne muscular dystrophy. In the third quarter of 2026, Keros reported roughly $40 million in revenue, largely milestone-driven, and positive net income, while cash and equivalents stood near $259.5 million.

What Could Support a Move Toward the Target

The strongest support is the gap between the current market capitalization—roughly $200 million—and the optionality embedded in the pipeline. Elritercept's late-stage, Takeda-partnered program offers near-term catalysts and potential milestone income, while rinvatercept represents a wholly owned growth avenue with initial Phase 2 data expected in the first half of 2027. A solid cash position, a modest $5 million share-repurchase authorization approved in September 2026, and a third-quarter earnings beat on both revenue and EPS (earnings per share) all help underpin the more optimistic targets. Analyst estimates were also revised higher by at least one firm following results.

What Could Prevent the Target From Being Reached

The primary obstacle is binary clinical risk. A failure or delay in elritercept or rinvatercept trials would remove the value most buy-rated analysts are modeling, and any renewed financing need could dilute existing holders. The steady erosion of price targets throughout 2026 signals waning conviction, and the resignation of the company's CFO in mid-2026 adds execution uncertainty. With no meaningful recurring product revenue and shares trading near their 52-week low after a roughly 50% year-to-date decline, investor sentiment remains fragile, and insiders have been net sellers in recent quarters.

Technical Levels and Market Structure

The chart reflects sustained downside pressure. Support sits in the $9–$10 zone, an area tested repeatedly in late 2026 and roughly matching the 52-week low, with the $10 round-number level acting as a psychological floor. On the upside, resistance is layered: the 50-day and 200-day moving averages have tracked near $11–$12, and prior breakdown areas in the $14–$16 range—roughly where the stock consolidated earlier in 2026—represent the first major hurdle on any path toward $19. Reaching the target would require not just a rebound but a decisive break back above these declining averages.

Time Horizon and What Investors Should Monitor

Analyst price targets for this stock generally reflect a roughly 12-month research horizon, though individual firms apply their own assumptions. Key items to watch include elritercept trial updates and regulatory interactions, initial rinvatercept Phase 2 data expected in the first half of 2027, quarterly cash burn and any changes to the Takeda collaboration, and analyst revisions following each data readout. Because Keros is pre-revenue on a product basis, clinical catalysts—not earnings multiples—will drive the share price. From what I see, this is important because clinical updates tend to move the stock more than any other factor.

Using AI Tools for Monitoring KROS

For traders monitoring stocks like Keros, AI Daily Buy/Sell Signals offers an automated way to track shifting conditions. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual scanning allows. I find it helpful to cross-check signals here alongside my own review of the clinical pipeline before making any decisions.

Final Assessment

The $19 target represents a calculated average of five current analyst price targets ranging from $16 to $23, and it requires a roughly 70% advance from a price near $11. The bull case rests on elritercept's late-stage, Takeda-partnered program and the optionality of rinvatercept, while the bear case points to a pre-revenue profile, a year of target reductions, and shares mired near their 52-week low. The wide spread between $16 and $25 shows analysts genuinely disagree about the pipeline's value. Whether KROS can reach $19 ultimately hinges on clinical data and milestone execution rather than valuation math, and investors should weigh that binary risk carefully. I'm watching this closely as the next set of trial updates arrives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KROS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


KROS in upward trend: price rose above 50-day moving average on November 17, 2026

KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Oscillator exited the oversold zone, 26 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 78 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.592). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on treatments for rare muscle diseases

Industry Biotechnology

Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
78
Web
https://www.kerostx.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.